| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Top-line Data example | Phase 2 | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Top-line Data example | Phase 2 | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Top-line Data example | Phase 2 | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Zura Bio Limited$5.43
-0.11 (-1.99%)
D 33Pipeline Score Richly Valued Biotech · Clinical
Market Cap
414.19 M
EPS
-1.22
P/E Ratio
-
Value Trade
2.65 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
14.75 M
Operating CF
-18.92 M
Total Assets
228.64 M
Total Liabilities
11.74 M
Equity
216.90 M
D/E Ratio
12,345
-7.43 %
Week
-18.5 %
1 Month
-29.9 %
3 Month
17.84 %
6 Month
-55.28 %
5 Year
-55.28 %
All Time
Cash Data
Cash Position
225.59 M
Monthly Burn
6.31 M
Runway
33.1 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
541.15 K
52 Week Range
0.98 - 7.44
% held by Insiders
33.39 %
% held by Institutions
67.6 %
Enterprise Value
188.60 M
Total Shares
94.93 M
Short %
19.71 %
Float Shares
52.02 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Zura Bio Limited
156Total events
6Upcoming
24Tier-1 (high impact)
2022 – 2027Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2Enrollment Complete
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutTibulizumabClinical Data
Subscribe to view catalyst details
TBD
▲Enrollment CompleteTibulizumabTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D33
Pipeline Score $4M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 45%
Micro Cap (rank 509 of 924)
Percentile RankZura Bio Limited faces pipeline headwinds (33/100), with 2 assets in development.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tibulizumab Dose A Monoclonal antibody | Hidradenitis Suppurativa (HS) | Phase 2 | NCT06993610 | 26% | $5M | ACTIVE NOT_RECRUITING | 225 | FAST | B (64) | Apr 1, 2027 | MODERATE_RISK | MEDIUM Jun 30, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
remibrutinib | hidradenitis suppurativa | — | 2024-04-23 | 72.7; 48.5; 34.7; 38.0 (21.1 to 55.0); 13.8 (4.4 to 32.0); 72.3; 48.5; 34.9; 37.2 (19.7 to 53.0); 13.9 (4.2 to 31.9); 99.9; 89.6 Read More | xA9;2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Advancing clinical outcomes through pioneering dual-pathway biology April 2024 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes   Read More | |
remibrutinib | hidradenitis suppurativa | — | 2024-04-23 | 72.7; 48.5; 34.7; 38.0 (21.1 to 55.0); 13.8 (4.4 to 32.0); 72.3; 48.5; 34.9; 37.2 (19.7 to 53.0); 13.9 (4.2 to 31.9); 99.9; 89.6 Read More | xA9;2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Advancing clinical outcomes through pioneering dual-pathway biology April 2024 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes   Read More | |
remibrutinib | hidradenitis suppurativa | — | 2024-04-23 | 72.7; 48.5; 34.7; 38.0 (21.1 to 55.0); 13.8 (4.4 to 32.0); 72.3; 48.5; 34.9; 37.2 (19.7 to 53.0); 13.9 (4.2 to 31.9); 99.9; 89.6 Read More | xA9;2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Advancing clinical outcomes through pioneering dual-pathway biology April 2024 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes   Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ZURA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ZURA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ZURA▲ +5.2%on this news
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
Zura Bio has successfully surpassed its enrollment targets for Phase 2 studies in Hidradenitis Suppurativa (HS) and Systemic Sclerosis (SSc). This achievement reflects the company's strong performance and commitment to advancing its Tibulizumab program. The expansion of this program highlights Zura Bio's strategic focus on addressing these challenging conditions.
Read more →ZURAZura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
Zura Bio has announced the appointment of Muzammil Mustufa as Chief Business Officer. This expansion of the leadership team is aimed at enhancing the company's strategic direction and growth potential. Mustufa's experience is expected to contribute positively to Zura Bio's objectives.
Read more →ZURA▼ -7.2%on this news
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio reported its financial results for the first quarter of 2026, highlighting the advancement of two Phase 2 studies for its drug tibulizumab. The company raised approximately $144 million through a public offering, bolstering its financial position, which is expected to fund operations through at least the end of 2028. Zura also expanded its leadership team to enhance its operational and scientific capabilities. However, the company recorded a net loss of $24.2 million, with increased R&D expenses reflecting investment in its clinical programs.
Read more →ZURAZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This move is part of their compliance with regulatory requirements, although specific details about the grants were not disclosed in the article.
Read more →ZURA▼ -10.1%on this news
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
Zura Bio Limited reported its financial results for the year ending December 31, 2025, highlighting significant progress in its Phase 2 clinical programs. The company raised $144 million to strengthen its balance sheet and is focused on advancing its lead candidate, tibulizumab. Anticipated data readouts from ongoing studies are expected in late 2026 and early 2027, positioning Zura for potential growth despite increasing net losses.
Read more →ZURACorporate overview
Zura Bio Ltd. presents its innovative bispecific antibody, Tibulizumab, designed to target both BAFF and IL-17 signaling pathways. The company is advancing two independent Phase 2 trials, TibuSHIELD and TibuSURE, which focus on addressing the unmet medical needs in diseases related to systemic sclerosis, a complex autoimmune condition. Tibulizumab represents a novel approach in the treatment landscape, enabling potential expansions into other autoimmune diseases pending clinical validation.
Read more →ZURAZura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
Zura Bio announced that its Phase 2 TibuSURE study design will be presented at the Systemic Sclerosis World Congress in March 2026. The study evaluates tibulizumab, a bispecific antibody targeting IL-17A and BAFF, in adults with systemic sclerosis. The trial aims to enroll 80 participants and will assess the drug's efficacy and safety over 24 weeks, with results expected in 2027.
Read more →ZURAZura Bio to Participate in Upcoming Investor Conferences
Zura Bio Limited will participate in two upcoming investor conferences in Miami, FL. The management team will engage in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026, followed by investor meetings at the Jefferies Biotech on the Beach Summit on March 11, 2026. The company is focused on developing novel therapies for autoimmune and inflammatory diseases.
Read more →ZURAZura Bio to Participate in Upcoming March 2026 Investor Conferences
Zura Bio Limited, a clinical-stage biotechnology firm, announced its participation in upcoming investor conferences, including the Leerink Global Healthcare Conference and the Jefferies Biotech on the Beach Summit. The company's management will engage with investors to discuss its innovative pipeline, which focuses on treatments for autoimmune and inflammatory diseases. Zura's lead candidate, tibulizumab, is currently in Phase 2 studies.
Read more →ZURAZura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Zura Bio Limited has successfully closed a public offering of Class A ordinary shares and pre-funded warrants, raising approximately $144 million. The offering included 21.2 million shares priced at $6.25 each, along with additional shares sold due to underwriters' full exercise of their purchase option. This funding will support Zura's clinical-stage development of novel therapies for autoimmune and inflammatory diseases.
Read more →ZURAZura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Zura Bio Limited has announced the pricing of its public offering of 18.2 million Class A ordinary shares at $6.25 each, aiming to raise $125 million. The offering includes pre-funded warrants for additional shares and is set to close on February 26, 2026, pending customary conditions. The funds will support Zura's clinical development of therapies for autoimmune diseases.
Read more →ZURAZura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants HENDERSON, NV.
Zura Bio Limited announced a proposed public offering of Class A ordinary shares and pre-funded warrants. The offering aims to enhance its financial resources, which is crucial for its development of medications targeting autoimmune and inflammatory diseases. The company plans to provide underwriters an option to purchase additional shares, although the completion of the offering depends on market conditions and other uncertainties. Detailed prospectus information will be made available through regulatory filings.
Read more →ZURA▲ +5.3%on this newsshared move
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
Zura Bio Limited has appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. Both appointees bring significant experience in immunology and drug development, which will support Zura's Phase 2 programs and growth opportunities. Neil Graham will step down from the Board on the same date.
Read more →ZURA▼ -5.7%on this news
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Zura Bio Limited will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. The company's senior leadership will engage in a fireside chat and conduct one-on-one investor meetings. Zura is focused on developing novel therapies for autoimmune and inflammatory diseases, with several candidates in various stages of clinical trials.
Read more →ZURAZura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
Zura Bio Limited has appointed Dr. Sandeep Kulkarni as its new CEO, effective January 21, 2026. He succeeds Kim Davis, who served as Interim CEO after Robert Lisicki's resignation. Dr. Kulkarni brings over two decades of experience in biotechnology and medicine, and he aims to lead Zura through critical upcoming clinical readouts.
Read more →ZURACorporate Overview
Zura Bio Ltd. provides an overview of Tibulizumab, a bispecific antibody designed to target both BAFF and IL-17 pathways, marking it as a unique approach in treating autoimmune diseases. The company is actively conducting two Phase 2 trials, TibuSHIELD and TibuSURE, which may unlock multi-billion dollar market potentials. Tibulizumab's dual-pathway strategy aims to address the complex immune mechanisms involved in diseases such as systemic sclerosis, which currently lack comprehensive treatment options.
Read more →ZURA▼ -9.7%on this news
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates Continued advancement of two Phase 2 clinical trials evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sc
Zura Bio Limited reported its third quarter financial results for 2025, highlighting progress in its ongoing Phase 2 clinical trials of tibulizumab. The company has a cash reserve of $139 million, which is projected to support operations until 2027. Despite competitive challenges and risks related to regulatory matters, Zura Bio continues to focus on disciplined study execution and patient recruitment in its clinical programs. Research and development expenses have increased due to the advancement of its clinical trials.
Read more →ZURAAdvancing Dual - Pathway Biologic Candidates in Autoimmune and Inflammatory Diseases September 2025 Nasdaq Ticker: ZURA 2025 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes "forward - lo
Zura Bio Ltd. is focused on advancing its dual-pathway biologic candidates in autoimmune and inflammatory diseases. The company is currently evaluating tibulizumab, its lead product, in two global Phase 2 studies with results expected in late 2026. Despite having $154.5 million in cash to support its operations until 2027, Zura Bio faces numerous uncertainties including regulatory hurdles and competitive pressures. The company has yet to commercialize any products and must overcome significant risks related to its clinical development programs.
Read more →ZURAZura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference HENDERSON, Nev. - (BUSINESS WIRE)
Zura Bio Limited has announced its participation in the upcoming Cantor Fitzgerald Global Healthcare Conference, set for September 4, 2025, in New York, NY. The company's senior leadership will engage in a fireside chat and conduct one-on-one meetings with investors. Zura Bio specializes in developing dual-pathway antibodies aimed at addressing unmet needs in autoimmune and inflammatory diseases. Their lead candidate, tibulizumab, is currently being evaluated in Phase 2 clinical studies for systemic sclerosis and hidradenitis suppurativa, along with other candidates in their pipeline.
Read more →ZURA▲ +8.2%on this news
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates Initiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa
Zura Bio Limited, a clinical-stage immunology company, reported its financial results for the second quarter of 2025, highlighting significant advancements in its clinical programs. Notably, the company initiated the TibuSHIELD Phase 2 study for adult patients with moderate to severe hidradenitis suppurativa. Financially, Zura Bio holds $154.5 million in cash, expected to sustain operations through 2027, though it reported a net loss of $16.0 million for the quarter. Leadership changes and ongoing clinical trials reflect the company's ambitious strategy, despite rising expenses and losses.
Read more →ZURAZura Bio Announces Chief Financial Officer Transition HENDERSON, NV - (BUSINESS WIRE)
Zura Bio Limited announced the appointment of Eric Hyllengren as the new Chief Financial Officer, effective July 7, 2025. This transition follows the departure of Verender Badial, who will stay on as a non-executive employee until July 31 to ensure a smooth changeover. Hyllengren brings extensive experience in financial leadership from the life sciences sector, including roles at Atara Biotherapeutics and Amgen. Zura Bio continues to focus on developing novel antibodies aimed at autoimmune and inflammatory diseases.
Read more →ZURA▲ +10.3%on this news
Advancing Dual-Pathway Biologic Candidates Addressing Unmet Needs in Autoimmune and Inflammatory Diseases Jefferies Global Healthcare Conference 2025 Wednesday
Zura Bio Ltd. is presenting tibulizumab, a dual-pathway biologic, at the Jefferies Global Healthcare Conference, highlighting its evaluation in Phase 2 trials for systemic sclerosis and hidradenitis suppurativa. Key milestones for the drug include topline data expected in mid-2025 and ongoing recruitment for the TibuSURE and TibuSHIELD trials, which may transition into open-label extensions. While the potential for improved outcomes is noted, concerns regarding the timeline for regulatory interactions and the unclear benefits of certain mechanisms may pose risks.
Read more →ZURAat the Jefferies Global Healthcare Conference
Zura Bio Limited will present a corporate overview at the Jefferies Global Healthcare Conference on June 4, 2025. The presentation will highlight the company's focus on developing dual-pathway antibodies targeting autoimmune and inflammatory diseases. Additionally, Zura Bio will hold one-on-one meetings with investors during the conference, aiming to strengthen investor relations. A live webcast of the presentation will be available, with an archived version accessible afterward.
Read more →ZURAZura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa TibuSHIELD has launched with the activation of its first clinical site This study is the first to evaluate
Zura Bio Limited has announced the launch of TibuSHIELD, a global Phase 2 clinical study to evaluate tibulizumab in adults with moderate to severe hidradenitis suppurativa. The study will enroll approximately 180 participants across the United States, Canada, and Europe, examining the drug's efficacy and safety over a 28-week period. Results for the primary efficacy endpoint are expected by the third quarter of 2026. Tibulizumab has not yet been approved for use and is being assessed for its potential to improve outcomes for patients with this challenging condition.
Read more →ZURAZura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates Advanced the Phase 2 TibuSURE clinical trial evaluating tibulizumab in adults with systemic sclerosis (SSc) Continued preparations for th
Zura Bio Limited reported its financial results for the first quarter of 2025, highlighting continued progress in its clinical programs, including the TibuSURE trial for systemic sclerosis and preparations for a new trial in hidradenitis suppurativa. The company enjoyed a solid cash position of $170.6 million but also reported an increased net loss compared to the previous year. Recent hires are expected to bolster the company’s operational capabilities. Overall, Zura Bio appears to be advancing its pipelines while facing rising operational costs.
Read more →ZURA▲ +10.4%on this news
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline
Zura Bio Limited reported its full-year financial results for 2024, indicating significant progress in its operational and clinical undertakings. The company highlighted key milestones, including the initiation of the Phase 2 TibuSURE trial for systemic sclerosis. Zura Bio's leadership expansion and improved cash position of $176.5 million add to its financial stability. Despite these advancements, the company faces a challenge with increased operational expenses and a notable net loss for the year.
Read more →ZURAZura Bio Ltd. Nasdaq Ticker: ZURA Advancing Dual - Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases March 2025 2025 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This co
Zura Bio Ltd. is making significant advancements in dual-pathway biologic candidates aimed at addressing unmet needs in autoimmune and inflammatory diseases. The company has notable projects in progress, including a Phase 2 study for its lead asset, tibulizumab, and strategic milestones planned over the next few years. Zura's experienced team has a strong history of executing growth strategies, positioning them favorably in the market. Furthermore, they project sufficient cash resources to support their operations through 2027.
Read more →ZURAZura Bio to Present at the Leerink Partners Global Healthcare Conference HENDERSON, Nev. - (BUSINESS WIRE)
Zura Bio Limited will participate in the Leerink Partners Global Healthcare Conference on March 11, 2025. The company's senior leadership team is set to host a fireside chat and investor meetings in Miami, FL. Zura Bio is focused on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, with several assets having completed Phase 1/1b studies. The presentation will be available online and archived for future viewing.
Read more →ZURA▼ -7.9%on this news
Zura Bio Ltd. Nasdaq Ticker: ZURA Advancing Dual - Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases January 2025 2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This
Zura Bio Ltd., trading under the ticker ZURA, is actively progressing its dual-pathway biologic candidates aimed at addressing unmet needs in autoimmune and inflammatory diseases. The company is currently conducting a Phase 2 study for its lead asset, tibulizumab, with a subsequent trial for hidradenitis suppurativa expected to begin in the second quarter of 2025. Zura Bio also has an experienced leadership team with a history of successful mergers and acquisitions, strengthening its strategic growth initiatives. Despite facing significant losses and regulatory uncertainties, the company’s financial runway is projected to support operations through 2027.
Read more →ZURAZura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults with Systemic Sclerosis TibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis. T
Zura Bio Limited has launched the TibuSURE study, a Phase 2 global clinical trial to evaluate tibulizumab in adults with systemic sclerosis. This study aims to assess the safety and efficacy of tibulizumab, which employs a dual-pathway targeting mechanism to address the complex autoimmune disease. The trial will involve approximately 80 participants and aims to tackle significant unmet medical needs in systemic sclerosis. Notably, tibulizumab is currently an investigational compound and has yet to receive regulatory approval.
Read more →ZURA▼ -17.8%on this news· ran to -28% by day 3
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis HENDERSON, Nev. - (BUSINESS WIRE)
Zura Bio Limited has announced the submission of a protocol to the FDA for a Phase 2 clinical study of tibulizumab, a dual-target antibody for systemic sclerosis. This pivotal trial aims to evaluate the safety and efficacy of tibulizumab in about 80 adults suffering from early diffuse cutaneous systemic sclerosis. Notably, systemic sclerosis is a rare autoimmune condition with limited treatment options, highlighting the significance of this development. If successful, tibulizumab may become a first-in-class treatment for this challenging condition, which primarily impacts the skin and lungs. The trial is expected to begin in Q4 2024.
Read more →ZURAZura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of sys temic sclerosis (SSc) in Q4 2024 and hidradenitis supp
Zura Bio Limited reported its financial results for the third quarter of 2024, highlighting significant advancement towards starting Phase 2 trials for tibulizumab targeting systemic sclerosis and hidradenitis suppurativa. The company maintains strong financial backing with cash and equivalents totaling $188.2 million, expected to fund operations until 2027. Despite a noticeable increase in net losses, Zura Bio remains optimistic about the therapeutic potential of tibulizumab for autoimmune diseases, having taken key steps towards regulatory compliance.
Read more →ZURAZura Bio to Participate in Two Upcoming Investor Conferences in November HENDERSON, Nev. - (BUSINESS WIRE)
Zura Bio Limited, a clinical-stage immunology company, announced its participation in two investor conferences in November 2024. The events will include a fireside chat at the Guggenheim Healthcare Innovation Conference and investor meetings in London hosted by Jefferies. Zura Bio is developing multiple dual-pathway antibodies aimed at treating autoimmune and inflammatory diseases, with three assets ready for Phase 2 trials. The company aims to provide effective treatments for conditions with unmet medical needs.
Read more →ZURAxA9;2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Three Unique Dual-Pathway Biologics, Clinically Validated for Therapeutic Areas with Unmet Needs September 2024 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer
Zura Bio Ltd. is poised to advance its pipeline of dual-pathway biologics targeting various therapeutic areas with significant unmet needs. The company is financially secure, with approximately $188 million available to support operations through 2027, and is led by a seasoned team noted for their substantial contributions to mergers and acquisitions. Key upcoming milestones are set to establish further clinical validation for their innovative therapies, including the promising antibody therapy, Tibulizumab, aimed at treating autoimmune diseases.
Read more →ZURAZura Bio to Present at Three Upcoming Investor Conferences in September Henderson, Nev.
Zura Bio Limited, a clinical stage immunology company, has announced its participation in three investor conferences scheduled for September. The presentations will cover the company's progress in developing novel dual-pathway antibodies targeted at autoimmune and inflammatory diseases. Zura Bio’s leadership team will host meetings at both in-person and virtual events, showcasing their advancements in clinical studies and upcoming therapeutic indications. This initiative is part of Zura Bio's broader commitment to engage with investors and stakeholders in the biopharma sector.
Read more →ZURAZura Bio Ltd. Nasdaq Ticker: ZURA Three unique dual - pathway biologics, clinically validated for therapeutic areas with unmet needs August 2024 2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communicati
Zura Bio Ltd. has announced the development of three dual-pathway biologics that have shown clinical validation for addressing unmet therapeutic needs. The lead compound, tibulizumab, is expected to enter a Phase 2 study by Q4 2024. The company anticipates achieving strategic milestones and numerous external readouts over the next three years, while maintaining a cash runway until 2027. However, it faces challenges including the absence of approved products and financial losses since its inception.
Read more →ZURAZura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in aut
Zura Bio reported its second quarter 2024 financial results, highlighting significant advancements in its development programs, particularly for tibulizumab. The company presented data at EULAR 2024 that underscores its dual-pathway antibody approach for treating autoimmune diseases. With a robust cash position and the initiation of Phase 2 studies in systemic sclerosis and hidradenitis suppurativa scheduled, Zura Bio continues to advance its strategic initiatives. Additionally, the recent appointment of Robert Lisicki as CEO and the formation of a Scientific Advisory Board are expected to bolster the company's research and business development efforts.
Read more →ZURAZura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants Henderson, NV
Zura Bio Limited has successfully completed its exchange offer and consent solicitation for its outstanding IPO warrants, which will be fully exchanged and delisted from Nasdaq as of August 26, 2024. As a part of this process, the company will issue 3,235,184 ordinary shares in exchange for the warrants. Furthermore, Zura Bio plans to use its right to exchange remaining untendered IPO warrants at an exchange ratio of 0.27 Class A ordinary shares per warrant by August 27, 2024. The company is also advancing multiple assets in its immunology portfolio, focusing on novel therapies for autoimmune and inflammatory diseases.
Read more →ZURAZura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants Henderson, NV
Zura Bio has announced the expiration and strong results from its Exchange Offer and Consent Solicitation relating to its warrants. Approximately 97.2% of the public warrants and 69.0% of the private placement warrants were validly tendered, leading to the approval of a Warrant Amendment. This amendment allows each outstanding IPO warrant to be converted into 0.27 shares of Class A common stock, which is a reduction from the initial exchange ratio. Zura Bio plans to accept all validly tendered IPO warrants and execute the Warrant Amendment promptly.
Read more →ZURA▼ -6.1%on this news
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation Henderson, NV
Zura Bio Limited has initiated a warrant exchange offer and consent solicitation aimed at simplifying its capital structure and reducing the potential dilutive impact of outstanding IPO warrants. The company offers holders the opportunity to exchange their warrants for Class A shares at a defined ratio. Approximately 40.7% of public warrant holders and 65.3% of private placement warrant holders have already agreed to tender their warrants. The offering period for this exchange will extend until August 8, 2024, pending any extensions by the company.
Read more →ZURAZura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024 Tibulizumab (ZB-106) was well tolerated and neutralized IL-17A and BAFF in a Phase 1 study in patients with Sjogren's syndrome Preclinical data de
Zura Bio presented promising data regarding its lead candidate, tibulizumab (ZB-106), at the EULAR 2024 congress. The drug, designed for treating Sjogren's syndrome, demonstrated good tolerability and effective target engagement in a Phase 1 study. Additionally, preclinical findings suggest its potential benefits in rheumatoid arthritis, supporting its clinical development. Zura Bio aims to advance tibulizumab into Phase 2 trials for systemic sclerosis and hidradenitis suppurativa in the upcoming quarters.
Read more →ZURA▼ -8.1%on this news
Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology Henderson, Nev
Zura Bio Limited has announced the establishment of a Scientific Advisory Board comprising distinguished specialists from rheumatology, dermatology, and immunology. This initiative aims to bolster the company's commitment to innovative translational and clinical science, particularly in developing treatments for autoimmune and inflammatory diseases. With experts leading this board, Zura Bio looks to enhance its understanding of disease pathogenesis and advance its Phase 2 initiatives in conditions such as systemic sclerosis and hidradenitis suppurativa. The board includes noted figures like Dr. Johann Gudjonsson and Dr. Dinesh Khanna, which underscores the company's strategic direction in complex therapeutic areas.
Read more →ZURA▼ -7%on this news· ran to -20% by day 3shared move
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024 Novel, dual-pathway antibody targeting IL-17A and BAFF is expected to enter
Zura Bio Limited announced that it will present preclinical data on tibulizumab (ZB-106), a novel dual-pathway antibody targeting IL-17A and BAFF for Sjogren's syndrome and rheumatoid arthritis, at the EULAR 2024 conference. The company aims to explore the potential of this therapy in a variety of autoimmune conditions. Furthermore, Zura Bio is moving forward with Phase 2 clinical development for systemic sclerosis and hidradenitis suppurativa in the coming years.
Read more →ZURAZura Bio Announces Participation in June Investor Conferences Henderson, Nev
Zura Bio Limited announced its participation in two upcoming investor conferences. The company's Chief Scientific Officer will engage in one-on-one meetings at the Jefferies Global Healthcare Conference on June 6, 2024, while the CEO will partake in a panel discussion at the Oppenheimer Novel Targets in Immunology Summit on June 24, 2024. Zura Bio is advancing its clinical pipeline, which includes three promising assets ready for Phase 2 trials, targeting autoimmune and inflammatory diseases.
Read more →ZURAZura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights - Ended Q1 2024 with $89.8 million in cash and closed oversubscribed $112.5 million private placement in April 2024 from new and existi
Zura Bio reported its financial results for Q1 2024, ending the quarter with $89.8 million in cash and successfully completing a $112.5 million oversubscribed private placement. The company announced new executive appointments, including Robert Lisicki as CEO and Kiran Nistala as CMO. Zura is on track to initiate Phase 2 clinical trials for tibulizumab targeting systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025. The capital raised is expected to support their ongoing development efforts through 2027.
Read more →ZURA▲ +5.1%on this news· ran to +33% by day 3
xA9;2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Advancing clinical outcomes through pioneering dual-pathway biology April 2024 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes  
Zura Bio Ltd. is advancing its clinical trial plans for tibulizumab, a dual-pathway biologic targeting hidradenitis suppurativa (HS). The company aims to release topline data from ongoing studies by 2026. Zura's positioning in the HS market is underscored by the significant unmet need, given that many patients remain inadequately treated. The firm's development strategy is informed by insights from related therapies, emphasizing its potential to become a market leader in HS treatment.
Read more →ZURAZura Bio Announces Robert Lisicki as CEO and Director - Succeeds Founding CEO, Dr. Someit Sidhu, who will continue as a Board Director - Recognized as inspirational industry leader with exceptional R&D, commercial and gl
Zura Bio has announced the appointment of Robert Lisicki as the new CEO, succeeding founding CEO Dr. Someit Sidhu, who will continue as a Board Director. Lisicki brings extensive pharmaceutical leadership experience and expresses excitement about leading Zura Bio into a critical phase of trial execution for tibulizumab. This transition is seen as a key milestone for the company, which is developing novel antibodies for autoimmune diseases. The company anticipates multiple clinical readouts over the next two years, aiming to validate its pipeline.
Read more →ZURA▲ +10.8%on this news· ran to +26% by day 3
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer - Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team build
Zura Bio Limited has announced its full year 2023 financial results, highlighting a successful Nasdaq listing and the strategic appointment of Robert Lisicki as the new CEO. The company noted an expansion of its clinical-stage immunology portfolio and a cash balance of $99.8 million expected to fund operations through 2026. Zura Bio is also preparing to initiate a Phase 2 trial for its lead asset, tibulizumab, later in 2024, amidst rising R&D expenses and a substantial net loss in the past year. The transition in leadership marks a key moment as the company aims to advance its portfolio in autoimmune and inflammatory diseases.
Read more →ZURAxA9;2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Building the Next Immunology Leader March 2024 ©2024 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward-looking statements&#x
Zura Bio Ltd. is focusing on establishing itself as a leader in the immunology sector by advancing its clinical pipeline through 2025. The company is preparing for crucial Phase 2 and Phase 3 trials for its leading candidates ZB-168 and torudokimab, which demonstrate promising efficacy and safety signals. With a seasoned management team and a commitment to on-time clinical execution, Zura Bio aims to validate its products in treating various autoimmune diseases. Their strategic roadmap outlines key milestones and objectives for continued growth and development in the market.
Read more →ZURAZura Bio Announces Participation at March Conferences Henderson, Nev
Zura Bio Limited announced that its senior management will attend three conferences in March 2024, including the Leerink Global Biopharma Conference, the Eighth Systemic Sclerosis World Congress, and BIO-Europe Spring. This participation highlights Zura Bio's commitment to engaging with investors and industry leaders. The company is advancing its pipeline of three innovative therapeutic assets that are Phase 2 ready, targeting immune and inflammatory disorders. Despite the positive developments, the company has acknowledged potential risks associated with its forward-looking statements as detailed in their SEC filings.
Read more →ZURA▲ +6.1%on this news· ran to +29% by day 3
Zura Bio Announces Participation at February Investor Conferences Henderson, Nev
Zura Bio Limited announced its participation in several investor conferences taking place in February 2024. The company's senior management will engage in 1x1 meetings and presentations at events such as the Oppenheimer Winter CEO Summit and Guggenheim Healthcare Talks. Zura Bio is focused on developing novel treatments for immune and inflammatory disorders and has three assets that have completed Phase 1/1b studies and are ready for Phase 2. Forward-looking statements highlight the potential risks and uncertainties related to their business operations.
Read more →ZURAxA9;2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Building the Next Immunology Leader 42nd Annual J.P. Morgan Healthcare Conference
Zura Bio Ltd. is advancing its clinical pipeline, particularly focusing on ZB-106, a dual antagonist targeting systemic sclerosis and other immunological conditions. The company is set to initiate pivotal studies for ZB-106, which has shown strong clinical safety in previous trials. Additionally, Zura Bio is exploring indications in dermatology, rheumatology, and respiratory diseases. The ongoing efforts aim to build a robust position in the immunology space, supported by a range of promising assets.
Read more →ZURAZura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio's Clini
Zura Bio has appointed Robert Lisicki as President and Kiran Nistala as Chief Medical Officer, enhancing its leadership team ahead of upcoming clinical trials. These experienced executives bring vast expertise in biopharmaceuticals and are poised to guide the company through multiple Phase 2 clinical trials set for 2024. Their appointments signal Zura Bio's commitment to developing innovative treatments for immune and inflammatory disorders. The company is focused on establishing itself as a leader in immunology with a robust pipeline of therapeutic candidates.
Read more →ZURAZura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit Henderson, Nev
Zura Bio Limited announced its participation in the upcoming 42nd Annual J.P. Morgan Healthcare Conference and the 2024 Dermatology Summit. The company's senior management will present insights into its clinical-stage pipeline, which includes three assets that have reached Phase 2 readiness. Zura Bio is focused on developing novel therapies for immune and inflammatory disorders, addressing significant medical needs. The presentations will be available as webcasts and will remain accessible on the company's website for 30 days following the events.
Read more →ZURAZura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok Henderson, Nev
Zura Bio Limited has announced that two of its immunology abstracts were accepted and presented at the World Allergy Congress in Bangkok. The abstracts focus on ZB-168, an anti-IL-7R monoclonal antibody, and ZB-880, a fully human monoclonal antibody targeting IL-33, both of which have potential applications in various immune and inflammatory disorders. These presentations mark significant advancements in Zura Bio's research efforts. The company has three assets that are Phase 2 ready and plans to develop them for diverse therapeutic applications.
Read more →ZURA▲ +10%on this news
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors Henderson, Nev
Zura Bio Limited has appointed Arnout Ploos van Amstel as a Non-Executive Independent Director to its Board of Directors, filling the vacancy left by Dr. Garry Neil. Ploos van Amstel has a rich history in the biotech sector, with notable achievements in immunology-related treatments during his tenure at Novartis. His expertise is anticipated to bolster Zura Bio's strategic direction as the company prepares to initiate new clinical trials for its developing therapies aimed at immune and inflammatory disorders.
Read more →ZURAZura Bio Ltd. Corporate Overview Last Updated: October 2023 Building the Next Immunology Leader 2023 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes "forward - looking statements" within
Zura Bio Ltd. has issued a corporate overview, highlighting its strategy to become a leader in immunology. The company is targeting a sizeable total addressable market, projected to reach approximately $21 billion by 2029, through its clinical-stage pipeline focusing on key immunology pathways. Zura Bio is led by an experienced management team and emphasizes its commitment to addressing unmet needs in autoimmune diseases. However, the company acknowledges various risks that could impact its projections, including market volatility and external economic factors.
Read more →ZURAZura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute Benaroya Research Institute to further characterize role of IL-7R in TSLP and IL-7 signaling pathways Agreement underscores Zura Bio's co
Zura Bio Limited has entered into a sponsored research agreement with the Benaroya Research Institute to further explore the role of Interleukin-7 receptor alpha (IL-7R) in Thymic Stromal Lymphopoietin (TSLP) and Interleukin-7 (IL-7) signaling pathways. This collaboration aims to enhance the understanding of how IL-7R regulates immune functions and may impact the treatment of immune and inflammatory disorders. Zura Bio is currently focused on the development of multiple therapeutic candidates, including ZB-168, a monoclonal antibody targeting IL-7R, aimed at addressing various immune-mediated conditions. The partnership will also be guided by Dr. Steve Ziegler, a notable expert in the field.
Read more →ZURAZura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights Focused on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist for systemic sclerosis and hidradenit
Zura Bio Limited has reported its financial results for Q2 2023, highlighting advances in its multi-asset pipeline, including its lead candidate ZB-106, a dual antagonist targeting IL-17 and BAFF for systemic sclerosis and hidradenitis suppurativa. With cash reserves of $113 million, the company is set to support its operations through 2026. Upcoming clinical trials for ZB-106 are anticipated to start in the second half of 2024, reflecting the company's focus on developing innovative treatments for immune and inflammatory disorders.
Read more →ZURABuilding the Next Immunology Leader Corporate Presentation - July 2023 2023 Zura Bio Ltd. This communication includes " forward - looking statements " within the meaning of the "safe harbor" provisions of the Private Sec
Zura Bio Ltd. recently presented a corporate overview outlining its strategic direction and forward-looking statements regarding its pipeline and financial health. The company highlighted multiple Phase 2-ready assets in important immunology indications, underscoring their experienced management team. Zura Bio also reported having over $100 million in capital, which positions it well for continued development through 2026. However, the presentation emphasized various risks, including potential volatility in security prices and legal uncertainties.
Read more →ZURA▼ -5.7%on this news· ran to -28% by day 1
Zura Bio to Join the Russell 2000 and Russell 3000 Indexes
Zura Bio Limited has announced its inclusion in the Russell 2000 and Russell 3000 Indexes effective June 26, 2023. This decision reflects the company's market capitalization as of April 28, 2023, and is expected to enhance visibility among investors. The CEO noted this move as a demonstration of market appreciation for Zura Bio's clinical pipeline and financing efforts. The next quarterly rebalancing will likely consider the increased market capitalization following recent capital raises.
Read more →ZURABuilding the Next Immunology Leader Last Updated: June 2023 zurabio Corporate Overview Disclaimer Forward Looking Statements Disclaimer This communication includes " forward - looking statements " within the meaning of t
Zura Bio is strategically positioned as a rising leader in immunology with innovative clinical programs and strong financial backing. The company completed approximately $80 million in financing and has successfully in-licensed several promising assets, including ZB-106, an engineered dual antagonist. Led by a seasoned team of drug development experts, Zura aims to deliver new treatments targeting unmet needs. However, the company acknowledges potential risks from legal proceedings, market volatility, and regulatory changes that may impact its future performance.
Read more →ZURA▲ +16.8%on this news
Zura Bio completes approximately $80 Million financing with the focus on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist Tibulizumab (ZB-106) was licensed from Eli Lilly and Company
Zura Bio Limited has successfully completed a private placement, raising approximately $80 million. The funds will facilitate the initiation of Phase 2 clinical trials for ZB-106, a dual antagonist targeting IL-17 and BAFF, in systemic sclerosis and hidradenitis suppurativa. The drug has previously demonstrated a safe profile in Phase 1b studies, providing a solid foundation for further development. This accomplishment is viewed as a significant milestone for the company as it advances its therapeutic programs.
Read more →ZURAZura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases Licensing a potential first-in-class, anti-I
Zura Bio Limited has announced an $80 million financing package alongside the licensing of tibulizumab (ZB-106), a potential first-in-class dual antagonist targeting IL-17 and BAFF for autoimmune diseases. The compound, which has shown an acceptable safety profile in prior studies for rheumatoid arthritis and Sjogren's syndrome, is set to enter Phase 2 development for systemic sclerosis and hidradenitis suppurativa in 2024. Zura Bio has partnered with Eli Lilly to further this promising asset, highlighting a strong strategy for future growth in the therapeutic space. The financing will aid the advancement of Zura's clinical-stage pipeline, including additional therapies under development.
Read more →ZURAZura Bio Announces Appointment of Chief Scientific Officer
Zura Bio Limited has appointed Michael D. Howell, Ph.D., as its Chief Scientific Officer and Head of Translational Science. Dr. Howell brings extensive experience from various leadership roles in the pharmaceutical sector, including his previous position at DermTech, Inc. He joined Zura Bio initially in 2022 and is expected to play a pivotal role in advancing the company's scientific efforts and clinical development pipeline. Zura Bio focuses on developing therapies for immune and inflammatory disorders, with several assets currently in Phase 2 development programs.
Read more →ZURA▼ -11.4%on this news· ran to -50% by day 3
SUMMARY UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following summary unaudited pro forma condensed combined financial information (the "Summary Pro Forma Information") presents the combination of th
Zura Bio Limited has released its unaudited pro forma condensed combined financial information following its business combination with JATT Acquisition Corp. This financial data reflects the historical financial performance of both companies, showcasing total expenses and net loss figures for the nine months ended September 30, 2022, as well as the period ended March 31, 2022. The combined statement indicates that JATT is treated as the acquired company while Zura remains the acquirer for accounting purposes. This forms a crucial part of understanding the financial landscape post-business combination.
Read more →ZURAZura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp Zura Bio Limited to trade on Nasdaq as a clinical-stage biotechnology company focused on immunology Business combination results in ap
Zura Bio Limited has completed its business combination with JATT Acquisition Corp, transitioning into a clinical-stage biotechnology firm focused on immunology. With this merger, Zura aims to leverage $65 million in cash proceeds to fund research and development activities. Starting March 21, 2023, shares will trade on Nasdaq under the ticker 'ZURA'. The management team, comprising seasoned industry leaders, aims to develop therapeutics targeting key immunology pathways.
Read more →ZURAJATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited London, UK
JATT Acquisition Corp shareholders have approved the proposed business combination with Zura Bio Limited, a clinical-stage biotechnology company. Over 95% of the shareholders participated in the vote, with nearly all, 99.9%, in favor of the acquisition. The closing of the business combination is anticipated to occur on March 20, 2023, with trading under the new ticker symbols expected to begin on March 21, 2023. Zura has promising assets focused on inflammatory diseases and is in clinical development stages.
Read more →ZURAJATT Acquisition Corp Announces Planned Transfer of Listing to NASDAQ in Connection with its Proposed Business Combination with Zura Bio Limited LONDON, UK
JATT Acquisition Corp has announced plans to transfer its listing from the NYSE to the NASDAQ in conjunction with its business combination with Zura Bio Limited. The transfer is expected to occur upon the deal's closure, with trading on NASDAQ anticipated to start on March 21, 2023. Zura Bio Limited, a clinical-stage biotechnology company, is advancing key assets aimed at treating alopecia areata and other inflammatory diseases. This strategic move is seen as beneficial for both companies as they navigate the merger process.
Read more →ZURAJATT Acquisition Corp's Proposed Business Combination with Zura Bio Limited declared effective by US SEC Record date of Feb 26 th 2023 established as well as; Extraordinary general meeting of shareholders to approve the
JATT Acquisition Corp's proposed business combination with Zura Bio Limited has been declared effective by the U.S. SEC, allowing for a shareholder vote on March 16, 2023. Zura Bio, a UK-based biotechnology firm, focuses on novel therapeutics for immune disorders and plans to advance two promising assets: ZB-168 and torudokimab. The successful combination could provide Zura with the necessary capital to enhance the development of these assets, demonstrating potential clinical benefits in various conditions. The meeting will facilitate shareholder participation for this significant corporate action.
Read more →ZURAJATT Acquisition Corp. and Zura Bio Limited Announce Definitive Business Combination Agreement to Create NYSE Listed Biotechnology Company Company advancing ZB-168, an anti-IL7R a monoclonal antibody, originally develope
Acquisition Corp. and Zura Bio Limited Announce Definitive Business Combination Agreement to Create NYSE Listed Biotechnology advancing ZB-168, an anti-IL7Ra monoclonal antibody, originally developed by Pfizer Inc., in multiple phase 2 clinical trials The transaction values th
Read more →ZURAJATT ACQUISITION CORP Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
JATT ACQUISITION CORP Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of July 16, 2021 F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of JATT Acquis
Read more →ZURAJATT Acquisition Corp Prices $120 Million Initial Public Offering New York, New York
JATT Acquisition Corp Prices $120 Million Initial New York, New York - July 14, 2021 - JATT Acquisition Corp (the "Company"), a newly organized blank check company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 12 mil
Read more →Competitive Position
How ZURA ranks across every disease it competes inCompetitive Position is a premium feature
See how ZURA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial